Transforming growth factor-beta accelerates osteoinduction in a craniofacial onlay model.
Recombinant human transforming growth factor beta 1 was added to a demineralized bone matrix (DBM) paste, formed into cylinders and implanted onto the cranial periosteum of New Zealand White rabbits. The TGF-beta was added at doses of 0, 0.3, 3, 30 and 75 micrograms per implant. When the implants were removed after six weeks, histomorphometric analysis of the implants showed that TGF-beta induced significantly higher levels of trabecular bone formation than in the controls (mineralized bone area 6.0 +/- 0.8, 6.0 +/- 1.2, 5.6 +/- 1.0, 10.1 +/- 1.5, and 10.8 +/- 1.4 mm2, respectively, P < 0.05), TGF-beta also caused greater resorption of the demineralized bone matrix carrier (matrix area 7.2 +/- 0.9, 6.8 +/- 1.4, 3.7 +/- 0.9, 2.7 +/- 1.2, 0.9 +/- 0.5 mm2, respectively, P < 0.02). Measurements of the osteoid demonstrated a more active bone surface and there was evidence of rapid bone remodeling. Similar results were obtained using TGF-5 beta, a new hybrid molecule. These results demonstrate the capacity of transforming growth factor beta in accelerating osteoinduction.
Kibblewhite
D J
DJ
Otolaryngology-Head and Neck Surgery, University Hospital, Vancouver, B.C., Canada.
Bruce
A G
AG
Strong
D M
DM
Ott
S M
SM
Purchio
A F
AF
Larrabee
W F
WF
D000704:Analysis of Variance; D000818:Animals; D001857:Bone Matrix / Q000502:physiology / Q000637:transplantation; D016466:CHO Cells; D006224:Cricetinae; D004343:Drug Implants; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D012886:Skull / Q000187:drug effects / Q000254:growth & development; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000494:pharmacology*
D004343:Drug Implants; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta